Cargando…

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA

BACKGROUND: Prostate-specific antigen (PSA) is widely used for prostate cancer screening, but low specificity results in high false positive rates of prostate biopsies. OBJECTIVE: To develop new risk assessment models to overcome the diagnostic limitation of PSA and reduce unnecessary prostate biops...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jing, Liu, Shuai, Gao, Dexuan, Ding, Sentai, Niu, Zhihong, Zhang, Hui, Huang, Zhilong, Qiu, Juhui, Li, Qing, Li, Ning, Xie, Fang, Cui, Jilei, Lu, Jiaju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354782/ https://www.ncbi.nlm.nih.gov/pubmed/28039477 http://dx.doi.org/10.18632/oncotarget.14214

Ejemplares similares

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
por: Su, Rui, et al.
Publicado: (2022)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
por: Fiamegos, Alexandros, et al.
Publicado: (2016)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
por: Dai, Zhihong, et al.
Publicado: (2021)

Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml(-1) in Western China
por: Gao, Xue-Dan, et al.
Publicado: (2021)

Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2017)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
por: Castro, Hugo A. Socrates, et al.
Publicado: (2018)

Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients
por: Klaassen, Zachary, et al.
Publicado: (2014)

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2016)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
por: Johnson, Michael H., et al.
Publicado: (2015)

Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
por: Liu, Shuai, et al.
Publicado: (2016)

DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml
por: Sun, Hongmei, et al.
Publicado: (2022)

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
por: Fang, Dong, et al.
Publicado: (2015)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL
por: Zheng, Yuxin, et al.
Publicado: (2022)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score
por: Fang, Dong, et al.
Publicado: (2016)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 ng/ml via a New Model to Reduce Unnecessary Prostate Biopsies
por: Zhao, Ruizhe, et al.
Publicado: (2014)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
por: Okcelik, Sezgin, et al.
Publicado: (2016)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
por: Sofikerim, Mustafa, et al.
Publicado: (2007)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
por: Tutrone, Ronald, et al.
Publicado: (2020)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rqmvof1hvu94ls4m24evlj1m2m